10x Genomics, Inc.

TXG

NASDAQ · Healthcare IT

$80.70

At close - Sep 22, 4:00 PM EDT - USD

Market Cap$10.25B

P/E-230.6x

52W High$82.68

Volume3.83M

VCP Research Verdict2026Q2

Cash Buffer Masks Revenue Decline and Losses

10x Genomics faces a decelerating revenue trajectory, with 2026Q2 revenue down 12.6% year-over-year to $151.0M, and persistent operating losses averaging around $20M per quarter. However, the company maintains a strong liquidity position with $502.5M in cash a...

Explore valuation models

MARKET ACTION

TXG price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

TXG+385.56%

S&P 500 (^GSPC)+13.20%

1-Year Return

TXG+518.87%

S&P 500 (^GSPC)+15.98%

3-Year Return

TXG+95.16%

S&P 500 (^GSPC)+85.90%

5-Year Return

TXG-49.17%

S&P 500 (^GSPC)+81.35%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E

-216.1x

Forward P/E

N/A

EV/EBITDA

N/A

FCF YieldCash Flow

1.4%

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

-216.1x

N/A

EV/EBITDA

N/A

Price/FCF

73.8x

15.6x

100th· High

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$3.96-95.1%

Base (Fair)$36.34-52.6%

Bull$4.76-94.1%

$3.96 Bear$36.34 Base$4.76 Bull

Current Market Price: $80.70

Trades at a 122.1% premium to Base DCF ($36.34)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue

$643M+5.2% YoY

Net income

-$44M+76.2% YoY

Free cash flow

$130M+2371.2% YoY

Operating margin

-17.2%+14.6 pts YoY

ROIC (TTM)-17.9%

Avg ROIC 5Y-

ROE (TTM)-5.8%

Piotroski Score4 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate7/12 (58%)

Revenue Beat Rate10/12 (83%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Aug 6, 2026	-$0.14+42.4% vs -$0.24	$151M+3.0% vs $147M
Q2 2026 May 7, 2026	-$0.10+65.5% vs -$0.29	$151M+3.0% vs $146M
Q1 2026 Feb 12, 2026	-$0.13+31.6% vs -$0.19	$166M+4.0% vs $160M
Q4 2025 Nov 6, 2025	-$0.22-214.3% vs -$0.07	$149M+4.6% vs $142M

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

5 Stories

PRNewsWire·Sep 10, 2026

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

GuruFocus·Sep 8, 2026

10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100

On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p

Zacks Investment Research·Sep 3, 2026

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

Benzinga·Sep 1, 2026

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Filtered for 10x Genomics, Inc.More Headlines

Compare before deciding

Benchmark TXG against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for 10x Genomics, Inc. (TXG)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
TXG10x Genomics, Inc.Current	$80.70	$10.25B	-230.57	5.25%	-6.77%	-5.78%	—
PACBPacific Biosciences of California, Inc.	$1.47	$456.58M	-0.81	3.89%	-82.49%	-4961.74%	—
ILMNIllumina, Inc.	$247.46	$37.44B	45.41	-0.78%	18.36%	31.08%	—
BRKRBruker Corporation	$61.21	$9.32B	-408.07	2.08%	-2.03%	-2.87%	—
FLGTFulgent Genetics, Inc.	$21.65	$614.87M	-10.99	13.83%	-26.05%	-7.91%	—
CDNACareDx, Inc	$56.49	$2.92B	-141.23	13.79%	24.23%	32.81%	—

Compare TXG vs Peers

10x Genomics, Inc. (TXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PACB

Most directly comparable listed peer for TXG.

Scale Benchmark

vs TMO

Larger-name benchmark to compare TXG against a more recognizable public peer.

Peer Set

Compare Top 5

vs PACB, ILMN, BRKR, FLGT

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

TXG SEC Filings & Documents

10x Genomics, Inc. (TXG) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Aug 6, 2026·SEC

Material company update

Jun 8, 2026·SEC

Material company update

May 7, 2026·SEC

10-K Annual Reports

FY 2026

Feb 13, 2026·SEC

FY 2025

Feb 13, 2025·SEC

FY 2024

Feb 15, 2024·SEC

10-Q Quarterly Reports

FY 2026

Aug 7, 2026·SEC

FY 2026

May 8, 2026·SEC

FY 2025

Nov 7, 2025·SEC

Get notified when TXG posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

TXG Frequently Asked Questions

10x Genomics, Inc. (TXG) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is 10x Genomics, Inc.'s revenue?

10x Genomics, Inc. (TXG) reported $616.9M in revenue for fiscal year 2025. This represents a 768% increase from $71.1M in 2017.

How fast is 10x Genomics, Inc. growing?

10x Genomics, Inc. (TXG) grew revenue by 5.2% over the past year. This is steady growth.

Is TXG profitable?

10x Genomics, Inc. (TXG) reported a net loss of $75.1M for fiscal year 2025.

Dividend & Returns

What is TXG's return on equity?

10x Genomics, Inc. (TXG) has a return on equity (ROE) of -5.8%. Negative ROE indicates the company is unprofitable.

What is 10x Genomics, Inc.'s free cash flow?

10x Genomics, Inc. (TXG) generated $121.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in TXG back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Aug 6, 2026

-$0.14+42.4%

vs -$0.24

$151M+3.0%

vs $147M

Q2 2026

May 7, 2026

-$0.10+65.5%

vs -$0.29

$151M+3.0%

vs $146M

Q1 2026

Feb 12, 2026

-$0.13+31.6%

vs -$0.19

$166M+4.0%

vs $160M

Q4 2025

Nov 6, 2025

-$0.22-214.3%

vs -$0.07

$149M+4.6%

vs $142M

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

TXG10x Genomics, Inc.Current

$80.70

$10.25B

-230.57

5.25%

-6.77%

-5.78%

—

PACBPacific Biosciences of California, Inc.

$1.47

$456.58M

-0.81

3.89%

-82.49%

-4961.74%

—

ILMNIllumina, Inc.

$247.46

$37.44B

45.41

-0.78%

18.36%

31.08%

—

BRKRBruker Corporation

$61.21

$9.32B

-408.07

2.08%

-2.03%

-2.87%

—

FLGTFulgent Genetics, Inc.

$21.65

$614.87M

-10.99

13.83%

-26.05%

-7.91%

—

CDNACareDx, Inc

$56.49

$2.92B

-141.23

13.79%

24.23%

32.81%

—